Clinical Research Directory
Browse clinical research sites, groups, and studies.
SNIFF Multi-Device Study 2
Sponsor: Wake Forest University Health Sciences
Summary
The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture. This goal of this study is to measure how much insulin the device delivers to the cerebrospinal fluid (CSF). In addition, this study will look at the effects of insulin administered intra-nasally on memory, and on blood levels of insulin.
Official title: SNIFF Multi-Device Study 2 - Study of Nasal Insulin to Fight Forgetfulness
Key Details
Gender
All
Age Range
55 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
13
Start Date
2020-07-16
Completion Date
2020-11-03
Last Updated
2026-10-07
Healthy Volunteers
Yes
Interventions
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.
40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Participants will be assigned to receive regular insulin either 40 or 20 IU administered through an intranasal nebulizer-like device.
Locations (1)
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States